» Articles » PMID: 37439692

Testing for Human Papillomaviruses in Urine, Blood, and Oral Specimens: an Update for the Laboratory

Overview
Specialty Microbiology
Date 2023 Jul 13
PMID 37439692
Authors
Affiliations
Soon will be listed here.
Abstract

Twelve high-risk alpha human papillomavirus (HPV) genotypes cause approximately 690,000 cancer cases annually, with cervical and oropharyngeal cancer being the two most prominent types. HPV testing is performed in laboratory settings for various applications of a clinical, epidemiological, and research nature using a range of clinical specimens collected by clinicians or by individuals (self-collected specimens). Here, we reflect on the importance and justification of using the right test for the right application and provide practical updates for laboratories either participating in or anticipating involvement in HPV testing in three specimen types, namely, urine, blood, and oral specimens, which are considered "alternative" specimens by many. In addition to clinician-collected cervical samples and self-collected cervicovaginal samples, first-void urine is emerging as a credible specimen for HPV-based cervical cancer screening, triage of HPV screen-positive women, monitoring HPV vaccine impact, and HPV testing in groups for which a less invasive sample is preferred. Detection of cell-free DNA (including HPV DNA) in blood has great promise for the early detection of HPV-attributable oropharyngeal cancer (HPV-AOC) and potentially other HPV-driven cancers and as an adjunct prognostic marker in long-term tumor surveillance, including treatment response. The moderate sensitivity of HPV testing in oral rinses or swabs at HPV-AOC diagnosis prevents its use in HPV-AOC secondary prevention but represents a promising prognostic tool in HPV-AOC tertiary prevention, where the HPV persistence in oral rinses throughout treatment may predict early HPV-AOC recurrences and/or the development of secondary HPV-AOC. The increasing sophistication of specific collection devices designed for alternative samples and the enhanced precision of novel molecular technologies are likely to support the evolution of this field and catalyze potential translation into routine practice.

Citing Articles

The viral landscape in metastatic solid cancers.

Mjelle R, Castro I, Aass K Heliyon. 2025; 11(4):e42548.

PMID: 40028540 PMC: 11870251. DOI: 10.1016/j.heliyon.2025.e42548.


Addressing Global Disparities in Cervical Cancer Burden: A Narrative Review of Emerging Strategies.

Gopalkrishnan K, Karim R Curr HIV/AIDS Rep. 2025; 22(1):18.

PMID: 39979520 PMC: 11842523. DOI: 10.1007/s11904-025-00727-2.


Oral human papillomavirus (HPV) prevalence and genotyping among healthy adult populations in the United States and Europe: results from the PROGRESS (PRevalence of Oral hpv infection, a Global aSSessment) study.

Alemany L, Felsher M, Giuliano A, Waterboer T, Mirghani H, Mehanna H EClinicalMedicine. 2025; 79:103018.

PMID: 39896062 PMC: 11786696. DOI: 10.1016/j.eclinm.2024.103018.


Optimization and analytical validation of the Allplex HPV28 genotyping assay for use in first-void urine samples.

Bell M, Baussano I, Rol M, Tenet V, Heideman D, Gheit T J Clin Microbiol. 2024; 63(2):e0140424.

PMID: 39723836 PMC: 11837537. DOI: 10.1128/jcm.01404-24.


A review of urinary HPV testing for cervical cancer management and HPV vaccine surveillance: rationale, strategies, and limitations.

Cheng L, Wang R, Yan J Eur J Clin Microbiol Infect Dis. 2024; 43(12):2247-2258.

PMID: 39400675 DOI: 10.1007/s10096-024-04963-z.


References
1.
Pattyn J, Van Keer S, Tjalma W, Matheeussen V, Van Damme P, Vorsters A . Infection and vaccine-induced HPV-specific antibodies in cervicovaginal secretions. A review of the literature. Papillomavirus Res. 2019; 8:100185. PMC: 6804463. DOI: 10.1016/j.pvr.2019.100185. View

2.
Baussano I, Sayinzoga F, Tshomo U, Tenet V, Vorsters A, Heideman D . Impact of Human Papillomavirus Vaccination, Rwanda and Bhutan. Emerg Infect Dis. 2020; 27(1):1-9. PMC: 7774553. DOI: 10.3201/eid2701.191364. View

3.
Costa S, Verberckmoes B, Castle P, Arbyn M . Offering HPV self-sampling kits: an updated meta-analysis of the effectiveness of strategies to increase participation in cervical cancer screening. Br J Cancer. 2022; 128(5):805-813. PMC: 9977737. DOI: 10.1038/s41416-022-02094-w. View

4.
Cho H, Shim S, Lee J, Hong J . Accuracy of human papillomavirus tests on self-collected urine versus clinician-collected samples for the detection of cervical precancer: a systematic review and meta-analysis. J Gynecol Oncol. 2021; 33(1):e4. PMC: 8728664. DOI: 10.3802/jgo.2022.33.e4. View

5.
Van Keer S, van Splunter A, Pattyn J, De Smet A, Herzog S, Van Ostade X . Triage of human papillomavirus infected women by methylation analysis in first-void urine. Sci Rep. 2021; 11(1):7862. PMC: 8042010. DOI: 10.1038/s41598-021-87329-1. View